| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Montelukast (as montelukast sodium) 4 mg oral granules sachet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely theophylline 10 milligram/1 milliliter conventional release oral solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline 65mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline 130mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline 260mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Xanthine bronchodilators |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing dextromethorphan and guaifenesin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin 600mg m/r/dextromethorphan 30mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin 1200mg m/r/dextromethorphan 60mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing guaifenesin and hydrocodone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing codeine and guaifenesin and pseudoephedrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline + dextrose |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing codeine and guaifenesin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing guaifenesin and pseudoephedrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing chlorphenamine and guaifenesin and hydrocodone and pseudoephedrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing guaifenesin and phenylephrine and phenylpropanolamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing guaifenesin and phenylephrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing dextromethorphan and guaifenesin and phenylpropanolamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing guaifenesin and phenylpropanolamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing dextromethorphan and guaifenesin and pseudoephedrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Montelukast 4mg chewable tablet (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Zileuton 600 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely guaifenesin 600 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dyphylline 250mg/2cc |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dyphylline 160mg/15ml elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely guaifenesin 1.2 gram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin 50mg/1mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin 400mg/10 mL liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin 800 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin 100mg/5mL oral liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin 300 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dyphylline 100mg/15mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dyphylline 200mg (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely diprophylline 400 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely guaifenesin 50 milligram/1 milliliter conventional release oral solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin 1 g oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely guaifenesin 675 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin 575 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline, anhydrous 80mg/15mL syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline, anhydrous 300mg (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely theophylline anhydrous 100 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline anhydrous 200 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely theophylline anhydrous 300 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline anhydrous 400 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely theophylline anhydrous 75 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline anhydrous 50 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline anhydrous 450mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline 100 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline 500mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline 80mg/15mL elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely theophylline 75 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline 100mg capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Zafirlukast 10 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Montelukast sodium 5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely montelukast sodium 4 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely theophylline anhydrous 125 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline 250 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline anhydrous 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline anhydrous 400 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline 300 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely theophylline anhydrous 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Brompheniramine maleate + guaifenesin + hydrocodone bitartrate 2mg/200mg/5mg syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dyphylline + guaifenesin 100mg/100mg elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dyphylline + guaifenesin 100mg/100mg liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dyphylline + guaifenesin 100mg/100mg syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely diprophylline 100 milligram and guaifenesin 100 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dyphylline + guaifenesin 100mg/50mg syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dyphylline + guaifenesin 200mg/100mg capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Diprophylline 200 mg and guaifenesin 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ephedrine hydrochloride + guaifenesin 6.25mg/100mg syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ephedrine sulfate + hydroxyzine hydrochloride + theophylline 6.25mg/2.5mg/32.5mg syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin + oxtriphylline 50mg/100mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin + oxtriphylline 50mg/100mg elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin + theophylline 100mg/150mg liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin + theophylline 100mg/80mg liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely guaifenesin 183 milligram and theophylline 305 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin + theophylline 200mg/150mg solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin + theophylline 90mg/150mg syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin 91.44 mg and theophylline 152.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin + theophylline sodium glycinat 100mg/300mg elixir (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin + theophylline, anhydrous 90mg/150mg liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Potassium iodide + theophylline, anhydrous 130mg/80mg elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline, anhydrous 100mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Guaifenesin 600mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aminophylline 25mg/mL injection solution 10mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aminophylline 25mg/mL injection solution 10mL amp |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aminophylline 250mg/10mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline 300mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline 50mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Theophylline, anhydrous 600mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing zileuton (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing diprophylline (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing guaifenesin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aminophylline m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aminophylline-containing product in rectal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aminophylline 250 mg rectal suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely aminophylline 500 milligram/1 each conventional release rectal suppository (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aminophylline 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aminophylline 105mg/5ml oral liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
agent de l'appareil locomoteur |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]